non inferiority

Related by string. noninferiority * NON . nOn . nons . - - Non . Non : Non GAAP Financial . non farm payrolls . Non Aligned Movement NAM . Non GAAP net . Non Brokered Private Placement . Non GAAP Measures . Non performing / Inferiority : inferiority complex . inferiority complexes . racial inferiority . numerical inferiority . intellectual inferiority . habitual inferiority complex * *

Related by context. All words. (Click for frequent words.) 79 noninferiority 70 primary endpoint 68 active comparator 67 primary efficacy endpoint 66 noninferior 66 achieved statistical significance 65 randomized multicenter 65 nonrandomized 65 primary efficacy endpoints 65 peginterferon alfa 2b 64 primary endpoints 64 multicentre randomized 63 REYATAZ r 63 secondary efficacy endpoints 63 secondary endpoints 63 efficacy endpoints 63 prospectively defined 62 secondary endpoint 62 plus ribavirin 62 prospective multicenter randomized 62 eplerenone 62 tecarfarin 62 lopinavir r 62 statistical significance 62 posaconazole 62 composite endpoint 62 TMC# C# 62 prospective randomized controlled 62 pegylated interferon alfa 2b 62 tapentadol ER 62 prospective randomized multicenter 61 efficacy endpoint 61 Non inferiority 61 multicenter randomized 61 prespecified 61 randomized controlled 61 LPV r 61 placebo controlled 61 ATACAND 61 subcutaneously administered 61 eptifibatide 61 abacavir lamivudine 61 pharmacokinetics PK 60 mg QD 60 mcg dose 60 oral rivaroxaban 60 prospective randomized 60 #mg QD [001] 60 multicentre 60 sirolimus eluting stent 60 ticagrelor 60 Phase 2b study 60 #mg BID [001] 60 piperacillin tazobactam 60 analgesic efficacy 60 tipranavir 60 viral kinetics 60 mg BID 60 insulin detemir 60 multicenter multinational 60 lispro 60 LEXIVA r 60 ENDEAVOR IV 60 multicenter randomized double 60 baminercept 60 ALVESCO 60 μg dose 60 ritonavir boosted 60 Taxus Stent 60 RE LY ® 60 multicenter randomized placebo controlled 60 nab paclitaxel 60 bioequivalence 60 pharmacodynamics PD 59 randomized Phase III 59 peginterferon alfa 2a 59 administered subcutaneously 59 tolerability 59 5-FU/LV 59 ACTEMRA TM 59 #mg BID [003] 59 PREZISTA r 59 randomized 59 dose escalation 59 viral kinetic 59 XGEVA 59 mcg kg 59 NEVO ™ 59 randomized controlled clinical 59 achieve statistical significance 59 budesonide 59 CANCIDAS 59 efficacy 59 comparator arm 59 EURIDIS 59 lixisenatide 59 ABC/3TC 59 edoxaban 59 dabigatran etexilate 59 FOLFOX 59 #mg/day [001] 59 insulin glargine 59 pertuzumab 59 pharmacokinetic equivalence 59 FOLPI 59 carboplatin paclitaxel 59 phase IIIb 59 BENICAR 59 mg dose 59 ribavirin RBV 59 candesartan cilexetil 59 fondaparinux 59 desvenlafaxine succinate 59 dose regimens 58 irbesartan 58 Engerix B 58 certolizumab 58 oxycodone CR 58 Phase III randomized 58 enoxaparin 58 #mg dose [003] 58 adalimumab 58 ARCOXIA 58 cilostazol 58 randomized placebo controlled 58 protease inhibitor PI 58 placebo 58 biphasic insulin aspart 58 dosing 58 placebo controlled randomized 58 double blinded placebo 58 pharmacodynamic properties 58 virologic failure 58 daily Infergen 58 ascending dose 58 oral diclofenac 58 linezolid 58 doripenem 58 vancomycin 58 CIMZIA TM certolizumab pegol 58 pharmacodynamic 58 TAXUS Stent 58 randomized double 58 xanthine oxidase inhibitor 58 DAPT 58 elagolix 58 febuxostat 58 placebo controlled trials 58 dosing regimen 58 teriflunomide 58 XIENCE V PROMUS Stent 58 MIRCERA 58 XIENCE V demonstrated 58 maximally tolerated dose 58 iniparib 58 sirolimus eluting 58 randomized clinical 58 efficacy tolerability 58 sustained virological response 58 tiotropium 58 placebo controlled clinical 58 abatacept 58 AIR CF2 58 plus COPEGUS 58 EDEMA3 58 HBeAg seroconversion 58 CIMZIA TM 58 Randomised 58 plus dexamethasone 58 controlled multicenter 58 FOLFIRI 58 pain palliation 58 bivalirudin 57 HCV RESPOND 2 57 zotarolimus eluting stent 57 idraparinux 57 mcg BID 57 pharmacokinetic PK 57 Pegasys ® 57 TAXUS Liberte Long 57 unfractionated heparin 57 pegylated liposomal doxorubicin 57 lanthanum carbonate 57 interferon alfa 2b 57 prucalopride 57 atazanavir ritonavir 57 randomized multicenter trial 57 mycophenolate mofetil 57 CYPHER ® Stent 57 ibandronate 57 BRIM2 57 plus prednisone 57 pharmacodynamic effects 57 achieved ACR# 57 chlorambucil 57 double blinded randomized 57 rilpivirine 57 RE LY 57 Taxotere ® 57 ug kg 57 COMBIVIR 57 peginterferon alfa 2a #KD 57 label multicenter 57 tocilizumab 57 mg/m2 dose 57 serum phosphorus 57 tobramycin 57 prospective multicenter 57 amoxicillin clavulanate 57 post hoc 57 Primary endpoints 57 Ambrisentan 57 pharmacokinetic parameters 57 CR nPR 57 mitoxantrone 57 mg TID 57 dose escalation trial 57 monotherapy 57 peg interferon 57 phase IIb 57 randomized multicentre 57 QD dosing 57 salmeterol fluticasone 57 multicenter placebo controlled 57 TAXUS Express Stent 57 virologic response 57 peginterferon 57 Randomized controlled 57 SPIRIT III 57 trials RCTs 57 sustained virologic response 57 dosing regimens 57 octreotide LAR 57 Darusentan 57 ULORIC 57 phase Ib 57 rolofylline 57 ritonavir boosted lopinavir 57 imipenem 57 velafermin 57 ROCKET AF 57 unfractionated heparin UFH 57 Phase IIIb 57 ritonavir boosted atazanavir 57 bosentan 57 lopinavir ritonavir 57 cangrelor 57 CCyR 57 multicenter 57 tigecycline 57 azilsartan medoxomil 57 Targretin 57 subgroup analyzes 57 lopinavir r arm 57 doxorubicin docetaxel 57 multicenter clinical 57 orBec 57 multicenter randomized controlled 57 tolerated dose MTD 57 phase IIb clinical 57 BARACLUDE ® 57 DU #b 57 interferon gamma 1b 57 NOXAFIL Oral Suspension 57 subanalysis 57 genotypic resistance 57 efavirenz EFV 56 EmbraceAC 56 galiximab 56 dalteparin 56 Peg IFN 56 GOUT 56 COPEGUS 56 PD LID 56 sirolimus eluting stents 56 rapid virologic response 56 #mg doses [002] 56 sunitinib 56 safety tolerability pharmacokinetics 56 #.#g/day 56 glargine 56 valsartan 56 secondary efficacy endpoint 56 APTIVUS 56 seroprotection 56 mCRC patients 56 undetectable HCV RNA 56 Betaferon ® 56 4mg/kg 56 reslizumab 56 tacrolimus ointment 56 pharmacokinetic profile 56 colesevelam HCl 56 Dabigatran etexilate 56 rosuvastatin 56 mITT population 56 intravenous dosing 56 #.#mg/dL 56 TDF FTC 56 abciximab 56 NSABP B 56 dosage regimens 56 BENICAR HCT 56 blinded randomized 56 alpha 2a 56 FOLFOX4 56 nicardipine 56 mRCC 56 Betaferon R 56 achieved PASI 56 clevidipine 56 etanercept 56 blind randomized 56 surrogate endpoint 56 pegylated interferon alfa 56 placebo controlled clinical trials 56 ONGLYZA 56 angiotensin receptor blocker ARB 56 TNF alpha inhibitor 56 μg kg 56 adefovir 56 adjunctive placebo 56 platelet inhibitor 56 vicriviroc 56 aldosterone antagonist 56 phase IIa 56 #mg/kg [002] 56 glatiramer acetate 56 thromboembolic events 56 postmenopausal osteoporotic women 56 degarelix 56 everolimus eluting stents 56 telmisartan 56 everolimus eluting stent 56 clazosentan 56 IOP lowering 56 Navelbine 56 mITT 56 pegylated interferon alpha 56 statistical significance p 56 ezetimibe simvastatin 56 tirofiban 56 statistically significant reduction 56 AIR CF1 56 NOXAFIL 56 CRESTOR #mg 56 SVR# 56 ISENTRESS 56 #mg QD [002] 56 indacaterol 56 oral FTY# 56 APPRAISE 56 prospective randomized placebo 56 mcg QD 56 oral vancomycin 56 Phase #/#a 56 oral ridaforolimus 56 mapatumumab 56 Ereska 56 risedronate 56 Acetate Rectal Suppositories 56 bicifadine 56 Phase 1b 56 null responder HCV 56 mg kg dose 56 clinically meaningful 56 randomized blinded 56 intermittent dosing 56 rivaroxaban 56 Tiotropium 56 Phase IIIb study 56 Cloretazine 56 pioglitazone 56 CLL8 56 thromboprophylaxis 56 insulin glargine rDNA origin 56 creatinine clearance 56 Phase IIa trial 56 FOSRENOL R 56 Efficacy 56 ustekinumab 56 dose escalation study 56 Xalatan R 56 pegylated interferon peg IFN 56 melphalan prednisone 56 sorafenib Nexavar 56 TRITON TIMI 56 pegylated interferon alfa 2a 56 Q2W 56 placebo controlled studies 56 bioequivalency 56 docetaxel 56 binary restenosis 55 mcg albinterferon alfa 2b 55 antiplatelet agent 55 AEGR 55 Phase 2a trial 55 Pharmacokinetic 55 DURATION 55 relapsed MM 55 deferoxamine 55 clinical endpoints 55 iclaprim 55 MoxDuo TM IR 55 serum phosphorous 55 #/#mg 55 diameter stenosis 55 Pharmacokinetic parameters 55 HBeAg negative patients 55 PEG IFN 55 NATRECOR R 55 vandetanib 55 therapeutic equivalence 55 nilotinib 55 mcg mL 55 voriconazole 55 mg qd 55 safety tolerability pharmacokinetic 55 angiographic outcomes 55 Capesaris 55 Fludara 55 gadobutrol 55 ACTEMRA 55 tamsulosin 55 dose proportionality 55 DLTs 55 ABSORB trial 55 Adalimumab 55 TLUS 55 GP IIb IIIa inhibitors 55 PROCTOCORT ® Suppository Hydrocortisone 55 CYPHER R Sirolimus eluting 55 multicentre randomized double 55 bendamustine 55 ziprasidone 55 randomized #:# 55 alvimopan 55 #mg/m# [002] 55 STRIDE PD 55 boosted protease inhibitor 55 cobicistat 55 ACR# response 55 placebo p = 55 TAXUS ATLAS 55 dosing intervals 55 TAXUS VI 55 FFNS 55 NEVO 55 MAGE A3 ASCI 55 clopidogrel 55 blinded randomized placebo controlled 55 Ceplene/IL-2 55 budesonide MMX 55 titrated glipizide 55 LB# [003] 55 antiviral efficacy 55 Carotid Revascularization Endarterectomy vs. 55 diabetic neuropathic pain 55 VELCADE melphalan 55 Cytoxan 55 CYPHER ® Sirolimus eluting 55 saline placebo 55 mcg 55 p = NS 55 ARB telmisartan 55 aflibercept 55 double blind placebo 55 BARACLUDE r 55 micafungin 55 g dL 55 ertapenem 55 NSABP C 55 blind multicenter 55 dose regimen 55 metastatic HRPC 55 SPIRIT IV 55 RE SURGE 55 Tarceva TM 55 eszopiclone 55 PRECiSE 55 zoledronic acid 55 ARIXTRA 55 clodronate 55 subcutaneous enoxaparin 55 tenofovir FTC 55 subcutaneous insulin 55 mg d 55 timolol 55 Corlux 55 tenofovir DF 55 NEVO TM 55 fluconazole 55 Xelox 55 IFN alfa 55 -#.# log# 55 AIR CF3 55 ONTARGET 55 Stenting Trial CREST 55 Dose escalation 55 pharmacokinetic PK study 55 Phase IIIb clinical 55 blind placebo 55 Phase IIa 55 CYPHER Stent 55 belimumab 55 KRN# 55 morphometric vertebral fractures 55 Noxafil 55 temsirolimus 55 undetectable HBV DNA 55 CHAMPION PLATFORM 55 Kaplan Meier analysis 55 masked placebo controlled 55 darbepoetin alfa 55 Fidaxomicin 55 CIMZIA ™ 55 FASLODEX 55 Tipranavir 55 pomalidomide 55 Taxotere R 55 Rebetol 55 Patency 55 mg tid 55 fluticasone propionate 55 lumbar spine BMD 55 ZOLINZA 55 EchoCRT 55 mg doses 55 Lantus ® 55 ENDEAVOR III 55 carotid artery stenting 55 Ranolazine 55 XELOX 55 HCV SPRINT 55 Doxil ® 55 #mg/day [002] 55 Phase 1b trial 55 dosed orally 55 dosing schedules 55 Phase IIa clinical 55 favorable pharmacokinetic profile 55 randomized controlled clinical trials 55 HbA1c levels 55 evaluating REVLIMID 55 caspofungin 55 COMFORT II 55 epoetin alfa 55 Phase Ib study 55 GFT# 55 phase IIa clinical 55 placebo controlled Phase III 55 ruboxistaurin 54 placebo controlled Phase 54 fluorouracil 54 GP IIb IIIa inhibitor 54 Folfox 54 Protelos 54 FDA defined valvulopathy 54 pioglitazone HCl 54 blinded placebo controlled 54 tolerability profile 54 SABCS 54 sorafenib tablets 54 NPH insulin 54 evaluable patients 54 fluticasone salmeterol 54 clopidogrel Plavix 54 tiotropium bromide 54 riociguat 54 NATRECOR ® 54 somatostatin analog 54 elotuzumab 54 Phase IIb trial 54 dexpramipexole 54 bezafibrate 54 KRAS mutations occur 54 CoFactor 54 PROMACTA 54 Clolar ® 54 Amrubicin 54 Copegus ribavirin 54 virologic 54 daunorubicin 54 IIIa inhibitor 54 placebo controlled dose escalation 54 Prospective Randomized 54 biologic therapy 54 Rivaroxaban 54 strontium ranelate 54 n = 54 APTIVUS r 54 nondiabetic patients 54 sevelamer carbonate 54 intravitreal injection 54 Roche Pegasys 54 RoACTEMRA 54 limiting toxicity 54 darunavir 54 Pegasys plus Copegus 54 AIM HIGH 54 randomization 54 DMARD 54 cisplatin vinorelbine 54 tasocitinib 54 multicenter Phase II 54 telaprevir dosing 54 RAPAFLO R 54 pharmacodynamic profiles 54 crizotinib PF # 54 oral Xeloda 54 eluting stent 54 pegylated interferon 54 prulifloxacin 54 Pivotal Trial 54 Prograf R 54 Omacetaxine mepesuccinate 54 epoetin alpha 54 reach statistical significance 54 NRTI 54 rizatriptan 54 investigational antiplatelet agent 54 seroconversion 54 blind placebo controlled 54 rt PA 54 Laquinimod 54 dose escalation clinical 54 multicenter prospective 54 tolvaptan 54 TELCYTA 54 retapamulin 54 Dasatinib 54 decitabine 54 statistically significant 54 IV bisphosphonates 54 amphotericin B 54 oral deforolimus 54 sirolimus stent 54 Pemetrexed 54 TAXUS 54 angiotensin II receptor blocker 54 carotid endarterectomy CEA 54 unblinded 54 retrospective observational study 54 tenofovir emtricitabine 54 PegIFN 54 pimecrolimus cream 54 phase 2a 54 timepoint 54 DAS# CRP 54 apremilast 54 YERVOY 54 Study GL# 54 peginterferon alpha 2a 54 seropositive patients 54 PEGINTRON TM 54 statistically significant efficacy 54 telaprevir dosed 54 #mg/m# [001] 54 dacarbazine chemotherapy 54 Prosaptide 54 insulin lispro 54 Phase 1a 54 UPLYSO 54 plus methotrexate 54 Xinlay 54 TAXUS Liberte Stent 54 Itopride 54 HBeAg positive patients 54 attain statistical significance 54 Sanofi Aventis Taxotere 54 mg BID dose 54 ACR# responses 54 tipranavir r 54 VAPRISOL 54 levosimendan 54 icatibant 54 evaluating Actimmune 54 #μg [002] 54 entecavir 54 LCP Tacro 54 rFVIIa 54 interferon ribavirin 54 PegIntron 54 ceftazidime 54 Increlex ® 54 REBETOL 54 GAMMAGARD 54 3mg/kg 54 ascending doses 54 febrile neutropenia 54 LIALDA 54 JANUVIA 54 inhaled iloprost 54 fluvastatin 54 vertebral fracture 54 venlafaxine XR 54 CALGB # [001] 54 dacarbazine 54 Inhalation Solution 54 ExTRACT TIMI 54 arzoxifene 54 GORE VIABAHN Endoprosthesis 54 Ixempra 54 docetaxel chemotherapy 54 RSD# oral 54 mg ustekinumab 54 dose escalation phase 54 lubiprostone 54 darunavir r 54 adefovir treated 54 albinterferon alfa 2b 54 statistically significant improvement 54 Subgroup analyzes 54 miconazole 54 ANCHOR trial 54 PRT# 54 infliximab 54 Phase 1b clinical 54 S/GSK# 54 label dose titration 54 interferon beta 1b 54 amlodipine 54 primary hypercholesterolemia 54 TAXUS p value 54 R# #mg BID 54 Viread Emtriva 54 STELARA 54 hour bronchodilation 54 INVEGA ® 54 #ug [001] 54 lamivudine 54 q8h 54 HORIZONS AMI trial 54 Panzem R NCD 54 ascending dose study 54 L PPDS 54 amprenavir 54 ACUITY trial 54 paclitaxel eluting stents 54 Onrigin TM 54 tanespimycin 54 TNF inhibitor 54 sitaxsentan 54 detectable HCV RNA 54 Phase 2b randomized 54 mg subcutaneously 54 Telbivudine 54 statistically significant superiority 54 TPV r 54 Degarelix 54 glufosfamide 54 Contrave# 54 aclidinium 53 Durezol 53 valopicitabine 53 pramlintide metreleptin combination 53 low dose dexamethasone 53 Phase IIb clinical 53 FOSRENOL ® 53 rHuPH# 53 randomisation 53 blind randomized placebo 53 Anturol TM 53 tacrolimus 53 AVADO 53 PFO migraine 53 LMWH 53 LEVADEX 53 BRIM3 53 AZILECT ® 53 ARIKACE 53 ORENCIA ® 53 basal bolus regimen 53 DSMB 53 PRIMO CABG 53 Traficet EN 53 Phase Ib II 53 Apidra ® 53 TYGACIL 53 Sorafenib HCC Assessment 53 telbivudine 53 fosamprenavir 53 KRAS status 53 nonsignificant 53 virus HCV protease inhibitor 53 low dose cytarabine 53 REVLIMID lenalidomide 53 Monotherapy 53 goserelin 53 Aclidinium 53 RezularTM 53 1mg dose 53 Cypher Stent 53 statistically significant p = 53 Aflibercept 53 infusional 5-FU/LV 53 virologically 53 CYPHER ® 53 Enoxaparin 53 lipid lowering therapy 53 TMC# r 53 Levemir 53 mg RDEA# 53 complete cytogenetic response 53 PEG Intron 53 Cancidas 53 Phase III pivotal 53 PEGylated anti 53 #.#/#.# mmHg [001] 53 ramipril 53 antipsychotic efficacy 53 pegylated interferons 53 delafloxacin 53 evaluable 53 BoNTA 53 zolmitriptan 53 dose cohort 53 thienopyridine 53 SPIRIT FIRST 53 confirmatory Phase III 53 Phase IIb 53 valacyclovir 53 EORTC 53 multicenter Phase III 53 peg IFN 53 LANTUS R 53 Secondary endpoints 53 intravenously administered 53 relapsing multiple sclerosis 53 definite stent thrombosis 53 budesonide pMDI 53 oral allopurinol 53 mg kg 53 cefazolin 53 baseline HbA1c 53 Kaletra lopinavir ritonavir 53 mCi kg 53 HbA1c 53 rosuvastatin #mg 53 darunavir ritonavir 53 brivaracetam 53 evaluating tivozanib 53 custirsen 53 randomized clinical trials 53 tenofovir disoproxil fumarate 53 HGS ETR1 53 pharmacodynamic PD 53 vinorelbine 53 R entecavir 53 Zenvia 53 inhaled corticosteroid ICS 53 subcutaneous SC 53 TMC# [001] 53 LCP Tacro ™ 53 dosage regimen 53 microbiologically evaluable 53 neurologic progression 53 pharmacokinetic pharmacodynamic 53 #:# randomization 53 statin monotherapy 53 dose titration 53 enfuvirtide 53 liposomal amphotericin B 53 cethromycin 53 pharmacodynamic profile 53 ACE inhibitor ramipril 53 recurrent GBM 53 Pivotal Phase 53 rasagiline 53 8mg/kg 53 ARCALYST ® 53 Perforomist Inhalation Solution 53 #mg dose [001] 53 dasatinib 53 urinary N telopeptide 53 NO# [002] 53 ASCEND HF 53 pharmacokinetic characteristics 53 Sustained virologic response 53 beclomethasone dipropionate 53 MabCampath 53 BROVANA 53 landmark ATHENA 53 trastuzumab DM1 53 Maximum Tolerated Dose 53 glycoprotein IIb IIIa inhibitor 53 candesartan 53 oral alendronate 53 vidofludimus 53 Atacand 53 μg 53 prespecified criteria 53 tolterodine ER 53 atovaquone 53 canakinumab 53 segment binary restenosis 53 SYMBICORT 53 AzaSite Plus 53 Phase III Clinical Trial 53 Monitoring ABPM 53 pemetrexed 53 β blockers 53 Capecitabine 53 reinfarction 53 Board DSMB 53 multinational multicenter randomized 53 dose escalation Phase 53 Intravitreal 53 pantoprazole 53 talabostat 53 placebo p 53 FOLFOX6 53 adriamycin 53 Cmax 53 hours postdose 53 IRESSA 53 Teriflunomide 53 Cimzia TM 53 oxaliplatin 53 Acute Ischemic Stroke 53 Hb A1C 53 treatment naive genotype 53 TAXUS stent 53 demonstrated clinically meaningful 53 Femara letrozole 53 RANK Ligand inhibitor 53 dose dose escalation 53 ongoing Phase 1b 53 oral anticoagulant 53 zonisamide SR 53 Trandolapril 53 revascularizations 53 Dapagliflozin 53 gefitinib 53 INCB# [001] 53 ACCOMPLISH 53 Lucentis monotherapy 53 levofloxacin 53 oral olanzapine 53 Peginterferon 53 TRANSFORMS 53 Mimpara 53 Nasacort AQ 53 peginterferon alfa 2a Pegasys 53 oxaliplatin Eloxatin 53 Prograf ® 53 zalutumumab 53 lacosamide 53 leukotriene receptor antagonists 53 FROVA 53 XIENCE V vs. 53 #mg dosing 53 ocrelizumab 53 pharmacokinetic PK profile 53 CALGB 53 PEG Intron ® 53 povidone iodine 53 ReoPro 53 Pharmacokinetic studies 53 landmark ATHENA trial 53 #mg BID [002] 53 metastatic hormone refractory 53 LymphoStat B 53 radezolid 53 fluoropyrimidine 53 teriparatide 53 NeuroSTAT ® 53 trabectedin 53 Telmisartan 53 sUA 53 imatinib therapy 53 Tocilizumab 53 Percutaneous Coronary Intervention 53 COPAXONE R 53 RE LY trial 53 QNEXA 53 #μg [001] 53 catheter occlusion 53 nitazoxanide 53 Epirubicin 53 TM Drug Eluting 53 Onbrez Breezhaler 53 hemoglobin A1c levels 53 Candesartan 53 Phase Ib clinical 53 Multiple Ascending Dose 53 Myocardial Infarction Study 53 pharmacokinetic profiles 53 lumiliximab 53 Randomized Evaluation 53 ASTEROID 53 clinically meaningful improvement 53 MIRAPEX 53 placebo dexamethasone 53 GSK# [001] 53 EVEREST II 53 NeoRecormon 53 NEXIUM 53 limiting toxicity DLT

Back to home page